bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

urlAlias

moreOnThisArticles

sponsorType

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Josephine Ma

China has approved military use of an experimental coronavirus vaccine developed by the People’s Liberation Army and a Chinese pharmaceutical company, in a first for the armed forces of any country.
The vaccine, identified as Ad5-nCoV, was jointly developed by a team at the Academy of Military Medical Sciences, led by Major General Chen Wei, and Tianjin-based company CanSino Biologics.
It is the first time that a vaccine candidate for Covid-19, the disease caused by the coronavirus, has been authorised for use for the military of any nation.
CanSino said on Monday that the candidate had been through two phases of clinical trials, which indicated it was safe and there was “relatively high” immune response to the antigen.


The candidate is yet to start phase three trials, which would confirm whether it could protect recipients from infection.
The military has approved its use for a year but it has not been authorised for civilian purposes.
Adding Ad5-nCoV to the People’s Liberation Army’s catalogue of special drugs means that it can be deployed in major outbreaks.
It is based on an Ebola vaccine that was developed by Chen but did not go into mass production.
Scientists are racing to find an answer to the coronavirus that has already infected more than 10 million people and killed over 500,000.
New cases continue to surge in the United States and India, with the US confirming more than 40,000 new cases for the third straight day on Monday.
According to the World Health Organisation, clinical trials are under way for 17 vaccine candidates, seven of which have been developed in China.
One candidate developed by Oxford University and AstraZeneca is in phase three studies.


Phase one and two studies typically test if a candidate is safe and whether it can generate an immune response from the recipients, but vaccines must complete all three sets of trials to be licensed.
CanSino said it completed phase two trials on June 11, but the company has not yet released data from the study.
Data from the first phase was published in The Lancet medical journal in May. Chen said at the time that the data showed that Ad5-nCoV was a potential candidate for further investigation.
Three other Chinese vaccine candidates have completed phase two trials, with promising results, according to their developers, but not data have been released.
Many Chinese candidates are planning phase three trials in other countries as the spread of the coronavirus in China is too limited to test the efficacy of the vaccine.
CanSino reached an agreement with Canadian government to conduct phase three trials there but details of the studies have not been revealed.


Chinese officials said earlier that some candidates could be approved for emergency use as early as September, meaning the potential vaccines could be given to people at high risk of the disease.
Sinopharm, a state-owned giant behind two candidates, said it had applied to administer their proposed vaccines to more than 1,000 volunteers from the company.
Phase one trials are also under way on an mRNA vaccine candidate developed by the Chinese military and a protein subunit vaccine developed by the Chinese Academy of Sciences.
An mRNA vaccine consists of an mRNA strand that codes for a disease-specific antigen. After injection into a human body, the cells would use the genetic information to produce the antigen. So far no human mRNA has ever been licensed.
Production has already started ahead of final results for some of the potential vaccines, including the Oxford University candidate, so that doses can be available once they are authorised for use.



JFK’s granddaughter says she has terminal cancer, criticises cousin RFK Jnr

UK ex-PM Boris Johnson hits back at ‘incoherent’ Covid inquiry report

Former UK government slammed for its initial Covid-19 response: ‘too little, too late’

RFK Jnr’s family members say he’s a threat to Americans’ health, call for his resignation

Coronavirus vaccine

China’s military becomes world’s first to use experimental coronavirus vaccine

An experimental coronavirus vaccine has been approved for use by the Chinese military – a first for the armed forces of any country. Photo: AFP

Chinese county sealed off after coronavirus spike linked to Beijing market

A northern Chinese county has imposed lockdown-like restrictions on its 400,000 residents after more than a dozen cases of coronavirus linked to the outbreak which started at a market in Beijing on June 11. Photo: EPA-EFE

Coronavirus: Chinese developer to start human trials in UAE for vaccine candidate

As the coronavirus pandemic continues to accelerate, scientists around the world are racing to develop a vaccine. Photo: AP

In this picture taken on April 29, 2020, an engineer shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing. - Sinovac Biotech, which is conducting one of the four clinical trials that have been authorised in China, has claimed great progress in its research and promising results among monkeys. (Photo by NICOLAS ASFOURI / AFP) / TO GO WITH Health-virus-China-vaccine,FOCUS by Patrick Baert

Global coronavirus death toll hits 500,000 as number of cases surges over 10 million

A health department worker of the Palestinian Hebron Municipality sterilises a street. Photo: AFP

(FILES) In this file photo taken on July 06, 2017 Shakira and Chris Martin from Coldplay perform together on stage during the Global Citizen Festival G20 benefit concert at the Barclaycard Arena in Hamburg, northern Germany on the eve of the G20 summit. - Music stars like Shakira, Coldplay, Usher or Justin Bieber will perform during a virtual concert on June 27, 2020 on the occasion of a donors conference to support the collection of donations in medical research against the Covid-19. (Photo by Ronny HARTMANN / AFP)

Coronavirus: Chinese firm says its vaccine candidate passes phase two clinical trials

Inside one of the new production facilities the China National Biotec Group (CNBG) has built for manufacturing a Covid-19 vaccines CNBG announced that one of the potential vaccine candidates had completed phase one and phase two clinical trials. Photo: The State-owned Assets Supervision and Administration Commission

(200608) -- BEIJING, JUNE 8, 2020 (Xinhua) -- A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing, capital of China, March 16, 2020. (Xinhua/Zhang Yuwei)

Chinese military scientists hope to test coronavirus vaccine abroad

A researcher works on developing a vaccine targeting the new coronavirus in east China’s Shanghai on January 29, 2020. Researchers around the world are racing to develop a vaccine. Photo: Xinhua

Chen Wei, a major general and top virologist of the PLA's Academy of Military Medical Sciences. Photo: Handout

News

China

Science

Military

Coronavirus

Greater China

Health & Medicine


Candidate developed by the PLA and CanSino Biologics added to armed forces’ list for one year
Proposed vaccine still to go through phase three clinical trials and cannot be used on civilians



Candidate developed by the PLA and CanSino Biologics added to armed forces’ list for one year.


China’s military becomes world’s first to use experimental coronavirus vaccine

Candidate developed by the PLA and CanSino Biologics added to armed forces’ list for one year Proposed vaccine still to go through phase three clinical trials and cannot be used on civilians

Candidate developed by the PLA and CanSino Biologics added to armed forces’ list for one year

Proposed vaccine still to go through phase three clinical trials and cannot be used on civilians